Blood pressure control; C – Cholesterollowing (“statin” class to reduce total cholesterol and low-density lipoprotein cholesterol), Cigarette quiting (complete cessation of smoking); D – Diabetes control (control of diabetes, Diet); E C Exercise (moderate exercise), Education health knowledge popularization education. Education health knowledge popularization education). Among them, the problem of lipid regulation therapy after bypass surgery appears to be particularly prominent, the misunderstanding of the understanding, resulting in clinical practice, lipid regulation therapy is not standardized widespread, standardize the lipid regulation therapy after bypass surgery urgently. Myth 1: after coronary artery disease bypass grafting, coronary artery disease has been cured, there is no need to adjust the lipid (lipid) therapy after coronary artery disease bypass grafting, restored the normal blood supply to the myocardium, lifting angina pectoris, to prevent the occurrence of serious complications, but the operation can not solve the atherosclerosis caused by the risk factors. Coronary heart disease is a chronic disease caused by multiple risk factors, and dyslipidemia is its most important risk factor. The most critical of the dyslipidemias are elevated total cholesterol (TC) and/or low-density lipoprotein cholesterol (LDL-C). Therefore, lipid regulation therapy after coronary artery bypass grafting is crucial. Misconception No. 2: No treatment is needed if the lipid test results are normal Looking only at the results of the lipid test, patients after bypass surgery often mistakenly believe that they have normal lipids and do not need to regulate lipids. The diagnostic criteria for hypercholesterolemia and the treatment target values are different for different patients. The higher the risk, the lower the diagnostic standard and the lower the standard value. Patients with existing myocardial infarction, post coronary artery bypass grafting and diabetes mellitus should be treated with aggressive lipid modulation. Pharmacologic therapy should be initiated when total cholesterol >5.20 mmol/L and LDL-C >3.12 mmol/L. The goal should be to reduce total cholesterol to <4.68 mmol/L and LDL-C to <2.60 mmol/L. Other recent studies have demonstrated that coronary artery disease should be treated with lipid modification even if there is no hyperlipidemia. Intensive lipid-modifying therapy can achieve greater clinical benefits. Myth 3: Statin lipid regulators have side effects and cannot be taken for a long period of time Statin can only be taken for a long period of time in order to benefit from it, and current clinical studies show that statin therapy for 3-5 years can significantly reduce deaths, strokes, and so on. The benefits of statin therapy far outweigh the side effects. 1 year of statin therapy saves 50-60 patients' lives per 1,000 patients, while the incidence of elevated liver enzymes is 0.5-2%, the incidence of myopathy is only 1/1,000, and the incidence of rhabdomyolysis, a serious side effect, is only 1-2/100,000 The occurrence of elevated liver transaminases, reducing the dose of the drug often leads to a decrease in the elevated transaminases, which often do not increase when the dose is increased again or when the same drug is selected. Statins can cause nonspecific myalgia or arthralgia in some cases, usually without an increase in creatine kinase (CK), and myositis occurs most often in patients with multiple comorbidities or on multiple medications. If a patient's CK is 10 times higher than the upper limit of normal values, especially in patients on combination medications, the medication should be discontinued, followed up, and treatment restarted when the symptoms disappear and the CK drops to normal. Therefore, as long as the rational application of statin lipid regulators under the guidance of physicians is very safe. Myth 4: Fish oil, lecithin and other health products can reduce fat, can replace statin lipid-regulating drugs A lot of people think that taking fish oil, lecithin and other health products can reduce blood lipids, in fact, this view is wrong. First of all, health care products are not drugs, no therapeutic effect, while the general health of people may play a role in health care. Clinical studies have found that fish oil preparations can reduce triglyceride mildly elevated, but the impact on total cholesterol and LDL-C is very small, and can not achieve the purpose of effective treatment of blood lipids. Fish oil can mainly supplement linoleic acid, conditions can be appropriate to supplement some, but can not replace the statin class lipid regulating drugs. Lecithin and other health products to lower cholesterol efficacy lack of clinical research evidence. So after bypass surgery patients must insist on taking statin lipid regulating drugs, and long-term standards. Long-term use of statins can significantly reduce the mortality rate after bypass surgery, the incidence of stroke and the chance of re-intervention or bypass treatment. Myth 5: After taking lipid-regulating drugs, normal blood lipids can be discontinued Many patients stop taking medication after the treatment reaches the standard, and some patients take and stop taking medication, all of which are wrong. Elevated blood lipids is a chronic metabolic abnormalities, and the treatment of hypertension, the current method of lipid regulation is only a symptomatic treatment, but can not cure the root cause. Lowering blood lipids requires long-term treatment, after the lipid regulation treatment reaches the standard, usually after stopping the drug for 1-2 weeks, the blood lipid level can rise again to the pre-treatment level. After the treatment reaches the standard, a long-term treatment plan should be formulated under the guidance of the doctor to effectively control the blood lipids in the long term and maintain them at a lower level, avoiding "three days of fishing, two days of sunshine net". Myth 6: After bypass surgery, only need to control the diet to achieve the purpose of lowering blood lipids Reasonable diet for patients after bypass surgery is very important, is the basis of lipid regulation therapy, but most of the bypass patients suffering from hyperlipidemia is mainly due to chronic metabolic abnormalities, that is to say, the main reason for the increase in blood lipids is the endogenous cause. Some people believe that hyperlipidemia after bypass surgery can be lowered by dietary control. However, this is not the case. Most of the patients will have a slight effect after dietary changes, only a few patients have a significant effect, and there are also patients whose LDL-C increases significantly instead of decreasing. This shows that dietary therapy can only be used as the basis of lipid regulation therapy, and dietary therapy alone cannot achieve the purpose of effectively lowering blood lipids, let alone reaching the blood lipid standard. In recent years, the international basic research on lipid regulation therapy has been progressing, the concept of lipid regulation has been updated, and the evidence of evidence-based medicine for lipid regulation therapy has been increasing. It has become an urgent task to popularize these new concepts, technologies and achievements and apply them to clinical practice in a timely manner.